Find Propentofylline manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 55242-55-2, Propentophylline, Hextol, Hwa 285, Karsivan, Hwa-285
Molecular Formula
C15H22N4O3
Molecular Weight
306.36  g/mol
InChI Key
RBQOQRRFDPXAGN-UHFFFAOYSA-N
FDA UNII
5RTA398U4H

Propentofylline
1 2D Structure

Propentofylline

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione
2.1.2 InChI
InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
2.1.3 InChI Key
RBQOQRRFDPXAGN-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(=O)C
2.2 Other Identifiers
2.2.1 UNII
5RTA398U4H
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(5'-oxohexyl)-3-methyl-7-propylxanthine

2. Hwa 285

3. Hwa-285

2.3.2 Depositor-Supplied Synonyms

1. 55242-55-2

2. Propentophylline

3. Hextol

4. Hwa 285

5. Karsivan

6. Hwa-285

7. 3-methyl-1-(5-oxohexyl)-7-propylxanthine

8. 3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione

9. 3-methyl-1-(5-oxohexyl)-7-propyl-1h-purine-2,6(3h,7h)-dione

10. 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-1h-purine-2,6-dione

11. 1h-purine-2,6-dione, 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-

12. Nsc-752424

13. 5rta398u4h

14. 3-methyl-1-(5-oxohexyl)-7-propyl-3,7-dihydro-1h-purine-2,6-dione

15. Ncgc00015861-04

16. Albert-285

17. Dsstox_cid_25189

18. Dsstox_rid_80736

19. Dsstox_gsid_45189

20. Propentofylina

21. Propentofyllinum

22. Hoe-285

23. Propentofylina [inn-spanish]

24. Propentofyllinum [inn-latin]

25. Cas-55242-55-2

26. Sr-01000075642

27. Brn 1156290

28. Unii-5rta398u4h

29. Viviq

30. Propentofylline [inn:ban:jan]

31. 3arx

32. Poy

33. Propentofylline, Solid

34. 3as2

35. Spectrum3_001834

36. Lopac-p-9689

37. Propentofylline (jan/inn)

38. Propentofylline [mi]

39. Lopac0_001015

40. Schembl74602

41. Bspbio_003507

42. Propentofylline [inn]

43. Propentofylline [jan]

44. 5-26-14-00082 (beilstein Handbook Reference)

45. Mls001060796

46. Hwa285

47. Propentofylline [mart.]

48. Chembl1079905

49. Dtxsid4045189

50. Propentofylline [who-dd]

51. Chebi:32061

52. Kbio3_003012

53. Hms2197a12

54. Hms3263k11

55. Hms3355f02

56. Zinc1915505

57. Tox21 110247

58. Tox21_110247

59. Tox21_501015

60. Bdbm50492435

61. Nsc752424

62. Akos016003243

63. Tox21_110247_1

64. Ccg-205095

65. Db06479

66. Lp01015

67. Nsc 752424

68. Sdccgsbi-0050988.p003

69. Ncgc00015861-01

70. Ncgc00015861-02

71. Ncgc00015861-03

72. Ncgc00015861-06

73. Ncgc00015861-07

74. Ncgc00015861-08

75. Ncgc00015861-09

76. Ncgc00094307-01

77. Ncgc00094307-02

78. Ncgc00094307-03

79. Ncgc00178023-01

80. Ncgc00261700-01

81. Smr000486263

82. Sbi-0050988.p002

83. 1-(5-oxohexyl)-3-methyl-7-propylxanthine

84. Db-052700

85. Hy-107203

86. Cs-0027629

87. Eu-0101015

88. Ft-0630675

89. D01630

90. P 9689

91. 242p552

92. Q2888695

93. Sr-01000075642-1

94. Sr-01000075642-5

95. Brd-k59273480-001-01-5

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 306.36 g/mol
Molecular Formula C15H22N4O3
XLogP30.7
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count4
Rotatable Bond Count7
Exact Mass306.16919058 g/mol
Monoisotopic Mass306.16919058 g/mol
Topological Polar Surface Area75.5 Ų
Heavy Atom Count22
Formal Charge0
Complexity454
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in alzheimer's disease.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Neuroprotective Agents

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)


5.2 ATC Code

N - Nervous system

N06 - Psychoanaleptics

N06B - Psychostimulants, agents used for adhd and nootropics

N06BC - Xanthine derivatives

N06BC02 - Propentofylline


5.3 Mechanism of Action

Propentofylline is a xanthine derivative and phosphodiesterase inhibitor with purported neuroprotective effects. It inhibits both phosphodiesterase and adenosine uptake. Phosphodiesterase has shown to associated with age-related memory impairment and Alzheimer's disease. -Amyloid protein 142 (42) can induce apoptosis in the cultured hippocampal neurons, suggesting that it plays an important role in causing neurodegeneration in Alzheimer's disease. Propentofylline is also capable of activating a cAMPPKA system, depressing the caspase cascade and modifying Bcl-2 family proteins. Propentofylline blocked both the apoptotic features induced by 42 and further induced an anti-apoptotic protein, Bcl-2. It suggests that the protection of propentofylline on the 42-induced neurotoxicity is caused by enhancing anti-apoptotic action through cAMPPKA system.


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty